6:14 PM
 | 
Dec 05, 2012
 |  BC Extra  |  Financial News

NovaBay planning follow-on

NovaBay Pharmaceuticals Inc. (NYSE-M:NBY) said late Wednesday it is planning a follow-on underwritten by Lazard. NovaBay was off $0.06 to $1.39 on...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >